XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Apr. 30, 2019
Jan. 01, 2019
Jan. 01, 2018
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues $ (17,548)   $ (21,416)   $ (25,619) $ (34,053)        
Increase in net loss 30,356 $ 42,203 $ 16,640 $ 20,187 72,559 $ 36,827        
Accumulated deficit $ (634,233)       (634,233)   $ (562,696)      
Topic 606 | Difference between Revenue Guidance in Effect before and after Topic 606                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Accumulated deficit                   $ 1,100
Topic 842                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Accumulated deficit                 $ (561,799)  
Topic 842 | Adjustments Due to the Adoption of ASC Topic 842                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Accumulated deficit                 $ 897  
Intangible Assets                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Reclassification adjustment             $ 600      
Pfizer                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues         $ (25,600)          
Pfizer | Customer Concentration Risk | Total revenues                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Percentage of revenues 26.00%   38.00%   16.00% 47.00%        
Brammer                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Option deposit               $ 3,000    
Option deposit, nonrefundable               1,500    
Kite Pharma Inc                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues $ (9,060)   $ (7,515)   $ (17,372) $ (7,515)        
Kite Pharma Inc | Customer Concentration Risk | Total revenues                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Percentage of revenues 52.00%   35.00%   18.00% 22.00%        
Bioverativ Inc                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues $ (3,059)   $ (4,516)   $ (5,009) $ (8,898)        
Bioverativ Inc | Customer Concentration Risk | Total revenues                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Percentage of revenues 17.00%   21.00%   61.00% 26.00%        
Collaboration Agreement | Pfizer                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues         $ (3,000)          
Manufacturing Capability Establishment | Brammer                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Other commitment               $ 2,000    
Change in Collaboration Agreement Scope | Collaboration Agreement | Pfizer                    
Organization And Summary Of Significant Accounting Policies [Line Items]                    
Decrease in revenues         3,000          
Increase in net loss         $ 3,000          
Increase in basic net loss per share (Usd per share)         $ 0.03